BofA Raises BrightSpring Health Services (BTSG) PT on BrightSpring Health to $31, Keeps a Buy Rating

BrightSpring Health Services Inc. (NASDAQ:BTSG) is one of the best growth stocks under $30 to buy. On September 10, BofA raised the firm’s price target on BrightSpring Health to $31 from $27.50, while keeping a Buy rating on the shares. While hospital fundamentals should remain solid in H2, BofA is concerned that the policy and reimbursement environment will be more negative compared to recent years.

In the previous month, BrightSpring Health Services also released its Q2 2025 earnings, where the company reported a total revenue of $3.1 billion, which marked a 29% increase year-over-year. Adjusted EBITDA also grew by 29% to $143 million. However, the EBITDA margin remained flat at 4.5% compared to the previous year. Gross profit for the quarter was $375 million, which was a 20% increase.

The Pharmacy Solutions segment was the primary growth driver, with revenue increasing 32% year-over-year to $2.8 billion. Within this segment, Infusion and Specialty Revenue saw a 39% increase, reaching $2.2 billion, and specialty scripts grew by 38%. Home & Community Pharmacy Revenue grew by 11% to $587 million. This growth, particularly in specialty scripts, was cited by CFO Jennifer Phipps as the factor for the increase in gross profit per script.

BrightSpring Health Services Inc. (NASDAQ:BTSG) is a home and community-based healthcare services platform in the US. It operates through two segments: Pharmacy Solutions and Provider Services.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.